# Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

> **NCT07524946** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Bausch Health Americas, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.

## Key facts

- **NCT ID:** NCT07524946
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07524946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07524946, "Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07524946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*